We have located links that may give you full text access.
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
Hepatology : Official Journal of the American Association for the Study of Liver Diseases 2023 September 22
BACKGROUND AND AIMS: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH), however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population.
APPROACH AND RESULTS: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n=7), 1 mg (n=42), 3 mg (n=55), or placebo (n=56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal dose. The primary end point was a change in ELF from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least squares mean difference in the change in ELF was ̶ 0.5 (95% confidence interval [CI], ̶ 0.7 to ̶ 0.2; p=0.0003) between the 3 mg group and the placebo group. 15%, 21% and 23% of patients in the placebo, 1 mg and 3 mg group, respectively, achieved fibrosis improvement ≥1-stage; and 13%, 16% and 20% achieved fibrosis improvement ≥1-stage without NASH worsening. Improvement in ALT, AST, Pro-C3 and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. 0%, 2% and 9% of patients in the placebo, 1 mg and 3 mg group, respectively, discontinued due to treatment-related adverse events.
CONCLUSIONS: Aldafermin 3 mg resulted in significant reduction in ELF in patients with compensated NASH cirrhosis.
APPROACH AND RESULTS: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n=7), 1 mg (n=42), 3 mg (n=55), or placebo (n=56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal dose. The primary end point was a change in ELF from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least squares mean difference in the change in ELF was ̶ 0.5 (95% confidence interval [CI], ̶ 0.7 to ̶ 0.2; p=0.0003) between the 3 mg group and the placebo group. 15%, 21% and 23% of patients in the placebo, 1 mg and 3 mg group, respectively, achieved fibrosis improvement ≥1-stage; and 13%, 16% and 20% achieved fibrosis improvement ≥1-stage without NASH worsening. Improvement in ALT, AST, Pro-C3 and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. 0%, 2% and 9% of patients in the placebo, 1 mg and 3 mg group, respectively, discontinued due to treatment-related adverse events.
CONCLUSIONS: Aldafermin 3 mg resulted in significant reduction in ELF in patients with compensated NASH cirrhosis.
Full text links
Related Resources
Trending Papers
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
Hemodynamic Support in Sepsis.Anesthesiology 2024 June 2
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness.European Respiratory Journal 2024 May 9
Axillary Surgery for Breast Cancer in 2024.Cancers 2024 April 24
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app